This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT03051256) in the REL-1017 25 mg ARM group. Side effects include: Dyspepsia with 11%, Headache with 11%, Vomiting with 5%, Fatigue with 5%, Somnolence with 5%.
1 Treatment Group
REL-1017 25 mg
1 of 1
600 Total Participants · 1 Treatment Group
Primary Treatment: REL-1017 · No Placebo Group · Phase 3
REL-1017 25 mg
Experimental Group · 1 Intervention: REL-1017 · Intervention Types: Drug
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved
Screening: ~3 weeks
Reporting: 52 weeks
Who is running the clinical trial?
Relmada Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
992 Total Patients Enrolled
Marco Pappagallo, MDStudy DirectorRelmada Therapeutics
7 Previous Clinical Trials
976 Total Patients Enrolled
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Adults aged between 18 and 65 years.
The patient was diagnosed with Major Depressive Disorder (MDD) after a Structured Clinical Interview for DSM-5 (SCID-5) for MDD.
The person is currently experiencing a major depressive episode.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
How old are they?
18 - 65
What site did they apply to?
Relmada Site 147
What portion of applicants met pre-screening criteria?